Valuation: Adaptive Biotechnologies Corporation

Market Cap 3.9B 3.47B 3.22B 2.91B 5.48B 369B 5.57B 38.58B 15.16B 193B 14.62B 14.32B 616B P/E 2026 *
-45x
P/E 2027 * -146x
Enterprise Value 3.72B 3.31B 3.07B 2.78B 5.23B 353B 5.32B 36.86B 14.48B 185B 13.97B 13.68B 589B EV / Sales 2026 *
12.7x
EV / Sales 2027 * 10.2x
Free-Float
97.95%
Yield 2026 *
-
Yield 2027 * -
1 day+1.96%
1 week-3.40%
Current month-15.50%
1 month-14.65%
3 months+11.71%
6 months+67.49%
Current year+50.37%
1 week 23.85
Extreme 23.85
25.91
1 month 23.85
Extreme 23.85
30.74
Current year 12
Extreme 12
30.74
1 year 12
Extreme 12
30.74
3 years 2.28
Extreme 2.28
30.74
5 years 2.28
Extreme 2.28
37.55
10 years 2.28
Extreme 2.28
71.25
Manager TitleAgeSince
Chief Executive Officer 51 07/09/2009
Director of Finance/CFO 42 07/04/2024
President 54 31/01/2018
Director TitleAgeSince
Chairman 51 -
Director/Board Member 63 31/01/2013
Director/Board Member 70 30/11/2013
Date Insider Type Main position Quantity % Market Cap. Importance
16/10/26 Exercice

Chairperson

35,643 0.0223%
13/10/26 Exercice

Chairperson

35,643 0.0223%
08/10/26 Exercice

Chairperson

35,643 0.0223%
Change 5-day change 1-year change 3-year change Capi.($)
+1.96%-3.40%+36.96%+492.72% 3.9B
+0.79%-6.16%+49.32%+74.50% 66.34B
-0.67%+5.60%+10.71%+88.71% 52.92B
+0.15%+4.69%+7.31%+73.25% 54.82B
+0.74%+2.75%+26.31%+45.29% 44.09B
+3.87%+10.15%+20.69%+132.73% 43.72B
+7.91%+4.30%+263.91%+602.72% 42.13B
-0.40%+9.85%+17.04%+59.17% 33.96B
-1.30%-0.68%+37.15%+7.04% 26.17B
+0.06%+4.88%+35.66%+25.52% 23.37B
Average +1.31%+4.13%+50.51%+160.16% 39.14B
Weighted average by Cap. +1.33%+4.77%+50.97%+131.71%

Financials

2026 *2027 *
Net sales 293M 261M 242M 219M 412M 27.8B 419M 2.9B 1.14B 14.55B 1.1B 1.08B 46.41B 359M 320M 296M 269M 505M 34.03B 513M 3.56B 1.4B 17.81B 1.35B 1.32B 56.81B
Net income -85.54M -76.14M -70.57M -63.94M -120M -8.1B -122M -847M -333M -4.24B -321M -314M -13.53B -26.11M -23.24M -21.54M -19.52M -36.69M -2.47B -37.3M -258M -102M -1.29B -97.95M -95.92M -4.13B
Net Debt -173M -154M -143M -129M -243M -16.4B -247M -1.71B -673M -8.58B -649M -636M -27.38B -217M -193M -179M -162M -305M -20.59B -310M -2.15B -845M -10.77B -815M -798M -34.37B
Projected Income Statement - Annual - Adaptive Biotechnologies Corporation
Logo Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
Employees
624
Date Price Change Volume
20/10/26 US$24.42 +1.96% 1,245,363
19/10/26 US$23.95 -0.29% 1,192,873
16/10/26 US$24.02 -6.10% 1,947,565
15/10/26 US$25.58 -0.16% 1,734,427
14/10/26 US$25.62 +1.34% 1,884,113
Trader
Investor
Global
Quality
ESG MSCI
BBB
MarketScreener Ratings - Adaptive Biotechnologies Corporation
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
24.42USD
Average target price
29.81USD
Spread / Average Target
+22.08%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Adaptive Biotechnologies Corporation
  1. Stock Market
  2. Stocks
  3. ADPT Stock